Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer

Sorafenib, the first agent developed to target BRAF mutant melanoma, is a multi-kinase inhibitor that was approved by the FDA for therapy of kidney and subsequently liver cancer, and is currently in clinical trials for thyroid, lung and brain cancer. Colorectal cancer with V600E BRAF mutation has sh...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Al-Marrawi, Mhd Yaser, Saroya, Bikramajit Singh, Brennan, Matthew C, Yang, Zhaohai, Dykes, Thomas M, El-Deiry, Wafik S
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Landes Bioscience 2013
Konular:
Bedside to Bench Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3841209/
https://ncbi.nlm.nih.gov/pubmed/23792568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.25191
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller